PROVIDER PROFILE · NPI 1407894975
Mehrdad MassumiMD
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
2,706
Unique beneficiaries
—
Total services
36,002
Distinct HCPCS
35
Medicare payment
$611K
Peer benchmark
Total Medicare services vs. 189 Physical Medicine and Rehabilitation providers in MD — top quintile (cohort median 1,801).
PRESCRIBING · PART D · 2024
Total Rx claims
1,347
Beneficiaries
—
Total drug cost
$18K
Distinct drugs
25
Brand share
11.3%
Top prescribed drugs
Gabapentin185 claims
Meloxicam150 claims
Omeprazole148 claims
Ropinirole Hcl131 claims
Tizanidine Hcl123 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2025
No data available for this provider in 2025.
REFERRAL NETWORK
Where Mehrdad Massumi's patients come from & go
Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 5 inbound referrers · 6 outbound destinations.
Receives referrals from
Inbound — who sends patients here
| Physician | Patients | Visits |
|---|---|---|
| AMERITOX, LLC | 34 | 85 |
| CHOICE LABORATORY SERVICES, LLC | 30 | 182 |
| Laboratory Corporation Of America Holdings Clinical Laboratory · Raritan, NJ | 25 | 51 |
| Quest Diagnostics Incorporated Md Clinical Laboratory · Baltimore, MD | 23 | 49 |
| FRANKLIN SQUARE HOSPITAL CENTER, INC | 11 | 30 |
Refers patients to
Outbound — where patients go next
| Physician | Patients | Visits |
|---|---|---|
| Md Spine Solutions Llc Clinical Laboratory · Reno, NV | 51 | 130 |
| Precision Toxicology, Llc Clinical Laboratory · San Diego, CA | 33 | 88 |
| Laboratory Corporation Of America Holdings Clinical Laboratory · Raritan, NJ | 25 | 52 |
| Quest Diagnostics Incorporated Md Clinical Laboratory · Baltimore, MD | 20 | 40 |
| AMERITOX, LLC | 18 | 24 |
| CHOICE LABORATORY SERVICES, LLC | 13 | 58 |
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
CROSS-REFERENCE